ArticleBMC cancer2025
Predicting cancer mortality using machine learning methods: a global vs. Iran analysis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer remains a leading cause of morbidity and mortality worldwide, with significant variations in incidence, mortality, and survival rates across regions. This study leverages Machine Learning (ML) to analyze global and Iran-specific cancer data, aiming to improve predictive accuracy for cancer mortality.
methodsUsing datasets from Global Cancer Observatory (GLOBOCAN) and the Iran National Cancer Registry (INCR), we evaluate the performance of ML models, including XGBoost, Random Forest, and Support Vector Machines, in predicting cancer outcomes.
resultsXGBoost achieved superior performance globally ([Formula: see text] = 0.83, AUC-ROC = 0.93) compared to Iran-specific data ([Formula: see text] = 0.79, AUC-ROC = 0.89), highlighting the influence of region-specific risk factors such as Helicobacter pylori infections in Ardabil. Additionally, we explore the application of ML in predicting Second Primary Cancer (SPC) risk, emphasizing the role of radiation dose, age, and genetic mutations as key predictors.
conclusionThis research underscores the potential of ML to inform personalized treatment plans and improve cancer care while addressing challenges such as data imbalances and regional disparities. The findings provide valuable insights for policymakers, researchers, and healthcare providers in developing targeted interventions to reduce the global cancer burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.